TY - JOUR
T1 - Neue systemische Therapieansätze bei malignen Augenlidtumoren
AU - Simon, Michael
AU - Steinberg, Florian T
AU - Niederau, Constantin E
AU - Wawer Matos Reimer, Philomena A
AU - Rokohl, Alexander C
AU - Heindl, Ludwig M
N1 - Rokohl: Zentrum für Augenheilkunde, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland
Centrum für Integrierte Onkologie (CIO) Aachen – Köln – Bonn – Düsseldorf, Köln, Deutschland; Heindl: externe Aff.
PY - 2025/5
Y1 - 2025/5
N2 - Malignant tumors of the eyelids represent a diagnostic and therapeutic challenge. Modern treatment approaches, such as targeted treatment and immunotherapy are becoming increasingly more important, particularly in advanced and metastatic stages; however, these can cause side effects such as fatigue, skin reactions and gastrointestinal complaints, which require close monitoring. An effective treatment option for advanced, metastasized or inoperable basal cell carcinoma is the well-manageable oral treatment with hedgehog inhibitors; however, these innovative, systemic treatment approaches require an individually adapted management, which is determined by an interdisciplinary tumor board and accompanied by a specialized, multiprofessional team to ensure optimal patient care.
AB - Malignant tumors of the eyelids represent a diagnostic and therapeutic challenge. Modern treatment approaches, such as targeted treatment and immunotherapy are becoming increasingly more important, particularly in advanced and metastatic stages; however, these can cause side effects such as fatigue, skin reactions and gastrointestinal complaints, which require close monitoring. An effective treatment option for advanced, metastasized or inoperable basal cell carcinoma is the well-manageable oral treatment with hedgehog inhibitors; however, these innovative, systemic treatment approaches require an individually adapted management, which is determined by an interdisciplinary tumor board and accompanied by a specialized, multiprofessional team to ensure optimal patient care.
KW - Humans
KW - Eyelid Neoplasms/therapy
KW - Carcinoma, Basal Cell/pathology
KW - Immunotherapy/methods
KW - Molecular Targeted Therapy/methods
KW - Antineoplastic Agents/therapeutic use
KW - Hedgehog Proteins/antagonists & inhibitors
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001466407100001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s00347-025-02235-5
DO - 10.1007/s00347-025-02235-5
M3 - Übersichtsarbeit
C2 - 40227329
SN - 2731-720X
VL - 122
SP - 342
EP - 348
JO - OPHTHALMOLOGIE
JF - OPHTHALMOLOGIE
IS - 5
ER -